UBS Group AG Grows Position in Dynavax Technologies Co. (NASDAQ:DVAX)

UBS Group AG boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAXFree Report) by 427.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 647,911 shares of the biopharmaceutical company’s stock after purchasing an additional 525,012 shares during the period. UBS Group AG owned about 0.50% of Dynavax Technologies worth $9,058,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Dynavax Technologies by 3.1% in the third quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after purchasing an additional 270,730 shares during the period. Dimensional Fund Advisors LP increased its stake in Dynavax Technologies by 7.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after buying an additional 293,337 shares during the period. Blair William & Co. IL lifted its holdings in Dynavax Technologies by 0.6% during the 3rd quarter. Blair William & Co. IL now owns 2,470,191 shares of the biopharmaceutical company’s stock valued at $36,485,000 after buying an additional 15,059 shares in the last quarter. Northern Trust Corp boosted its position in Dynavax Technologies by 1.7% in the 3rd quarter. Northern Trust Corp now owns 1,446,728 shares of the biopharmaceutical company’s stock valued at $21,368,000 after buying an additional 23,623 shares during the period. Finally, Eventide Asset Management LLC grew its stake in Dynavax Technologies by 38.9% in the 3rd quarter. Eventide Asset Management LLC now owns 1,425,000 shares of the biopharmaceutical company’s stock worth $21,047,000 after acquiring an additional 398,914 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Up 2.8 %

Shares of NASDAQ DVAX opened at $12.32 on Tuesday. Dynavax Technologies Co. has a 12-month low of $10.48 and a 12-month high of $15.15. The stock’s fifty day simple moving average is $11.69 and its two-hundred day simple moving average is $12.72. The stock has a market capitalization of $1.61 billion, a PE ratio of 205.33 and a beta of 1.20. The company has a current ratio of 15.20, a quick ratio of 14.10 and a debt-to-equity ratio of 0.36.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $50.79 million for the quarter, compared to the consensus estimate of $51.98 million. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. As a group, analysts expect that Dynavax Technologies Co. will post 0.12 EPS for the current fiscal year.

Insider Transactions at Dynavax Technologies

In related news, Director Francis Cano sold 3,615 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the completion of the sale, the director now owns 36,905 shares of the company’s stock, valued at $440,276.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Thursday, May 9th. Finally, StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Dynavax Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.33.

Read Our Latest Research Report on Dynavax Technologies

About Dynavax Technologies

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Further Reading

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXFree Report).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.